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OBJECTIVES The object of this study was to determine the effect of pre-treatment with clopidogrel in
patients undergoing elective stent implantation.
BACKGROUND The treatment of patients with adenosine diphosphate receptor blockers after percutaneous
coronary intervention (PCI) with stent implantation has been shown to decrease the
incidence of subacute stent thrombosis. Furthermore, non-randomized studies on pre-
treatment with clopidogrel among patients undergoing stent implantation have suggested a
reduction in myocardial damage and clinical events. The effect of pre-treatment with
clopidogrel has been studied in only a few randomized trials.
METHODS In a randomized trial, three days of pre-treatment with clopidogrel was compared with
standard post-procedural treatment in 203 patients undergoing elective stent implantation.
The primary end point was a rise in troponin I or creatine kinase-MB fraction (CK-MB)
serum levels at 6 to 8 and 16 to 24 h after PCI. Secondary end points were death, stroke,
myocardial infarction, coronary bypass grafting, repeated PCI, and subacute stent thrombosis
at one and six months after PCI.
RESULTS No difference was found between non–pre-treated and pre-treated patients in the post-
procedural elevation of troponin I (42 [43.3%] vs. 48 [51.1%], respectively, p  0.31) or
CK-MB (6 [6.3%] vs. 7 [7.4%], respectively, p 0.78). Adjustment for possible confounding
factors did not change these findings. Patient follow-up at one and six months showed no
significant difference between the treatment groups in death, stroke, myocardial infarction,
coronary artery bypass grafting, repeated PCI, or subacute stent thrombosis.
CONCLUSIONS In this randomized study, no beneficial effect of pre-treatment with clopidogrel on
post-procedural elevation of troponin I and CK-MB or on clinical events after one and sixth
months could be demonstrated. The study suggests that among patients with stable coronary
syndromes in whom coronary stent implantation is planned, pre-treatment may not be
beneficial in reducing early myocardial damage. (J Am Coll Cardiol 2004;44:20–4) © 2004
by the American College of Cardiology Foundationp
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Sptimizing anti-platelet therapy is an important matter in
eveloping future treatment strategies for patients undergoing
ercutaneous coronary intervention (PCI) with stent place-
ent. Treatment with clopidogrel, in addition to aspirin, has
een shown to decrease the risk of ischemic complications of
hese patients (1–3). Whether pre-treatment with this medi-
ation also decreases this risk is subject to debate.
See page 25
A sub-study of the Clopidogrel in Unstable angina to
revent Recurrent Events (CURE) trial demonstrated a
eneficial effect of clopidogrel among patients with unstable
oronary syndromes after 30 days when clopidogrel treat-
ent was started 3 to 10 days before PCI was performed
4–6). In the Clopidogrel for the Reduction of Events
uring Observation (CREDO) study, patients with stable
oronary syndromes were randomized to 3 to 24 h of
From the Amsterdam Department for Intervention Cardiology (ADIC), Onze
ieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Manuscript received June 10, 2003; revised manuscript received February 5, 2004,2ccepted February 10, 2004.re-treatment with clopidogrel or placebo, but no signifi-
ant difference was found between the treatment groups
fter 30 days (7). The observation was made, however, that
atients who received clopidogrel 6 h before PCI seemed
o have a more favorable outcome. Among stable, non-diabetic
atients, a smaller randomized trial found no difference in
linical events between pre-treated and non–pre-treated pa-
ients after one year (8). Whether pre-treatment with clopi-
ogrel decreases minimal myocardial damage in stable patients
as not been studied in a randomized study.
We performed a randomized study evaluating the occur-
ence of elevation of troponin I and creatine kinase-MB
raction (CK-MB) within 24 h after elective coronary stent
mplantation in patients pre-treated for three days with clopi-
ogrel compared with patients starting clopidogrel treatment
mmediately after the procedure. Also, we examined the
revalence of clinical events after one and six months.
ETHODS
tudy protocol. Between August 2000 and March 2002,
03 patients were enrolled at our hospital and scheduled to
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July 7, 2004:20–4 Clopidogrel Pre-Treatment in Elective Stentingndergo elective PCI with stent implantation. Patients were
andomized into two groups. In the control group the loading
ose of 300 mg clopidogrel was administered immediately after
oronary stent implantation; the second group underwent
re-treatment with 300 mg of clopidogrel three days before
oronary stent implantation followed by 75 mg once daily.
oth groups were treated with clopidogrel 75 mg once daily for
our weeks after the coronary intervention in combination with
spirin 100 mg once daily for at least six months.
During diagnostic angiography, angiographic character-
stics were recorded. The procedure was routinely per-
ormed by radial artery puncture, unless contraindicated. At
he beginning of each procedure, a bolus of 10,000 IU of
eparin was given intravenously, and for every additional
our of the procedure a further bolus of 5,000 U was
Table 1. Baseline Clinical Characteristics of Pa
Percutaneous Coronary Intervention
Characteristic
(Total, n  203)
Age (yrs), mean (SD)
Gender (percentage female), n (%)
Diabetes, n (%)
Hypertension, n (%)
Hypercholesterolemia, n (%)
Positive family history for CVD, n (%)
Smoker, n (%)
Previous MI, n (%)
Previous PTCA, n (%)
Previous CABG, n (%)
Use of beta-blocking agents, n (%)
Use of calcium antagonist, n (%)
Use of nitrates, n (%)
Use of insulin, n (%)
Use of statin, n (%)
Use of aspirin, n (%)
Use of ACE inhibitor, n (%)
Use of ATII antagonist, n (%)
Use of GP IIb/IIIa inhibitors, n (%)
Anginal class, n (%)
Class 0
Class 1
Class 2
Class 3
Class 4
*Statistically significant (p value 0.05).
ACE  angiotensin-converting enzyme; ATII  angi
cardiovascular disease; GP  glycoprotein; MI  myoca
Abbreviations and Acronyms
PCI  percutaneous coronary intervention
CABG  coronary artery bypass grafting
CK-MB  creatine kinase-MB fraction
CREDO  Clopidogrel for the Reduction of Events
During Observation study
CURE  Clopidogrel in Unstable angina to prevent
Recurrent Events trial
GP  glycoprotein
MI  myocardial infarctionangioplasty.dministered. Overnight heparin infusion and post-
rocedural usage of glycoprotein (GP) IIb/IIIa inhibitors
ere at the physician’s discretion.
Blood samples were taken at baseline, 6 to 8 h, and 16 to
4 h after PCI. Clinical events such as death, coronary
rtery bypass grafting (CABG), repeated PCI, myocardial
nfarction (MI), stroke, and access site bleeding were as-
essed. The follow-up took place in the outpatient clinic or
y means of telephone interview after one and six months.
ollow-up was completed in 99.5% of the cases.
The physicians were blinded to patient drug assignment
oth during stent implantation and during the assessment of
ollow-up data. All patients gave informed consent. The
tudy was approved by the medical ethical committee of our
nstitution.
atients. Patients were excluded from enrollment in cases
f primary intervention for acute MI or other emergency
rocedures, elevated baseline troponin I or CK-MB levels,
nown intolerance of clopidogrel or aspirin, long-term use
f non-steroidal anti-inflammatory drugs, planned peri-
rocedural treatment with GP IIb/IIIa inhibitors, or known
hrombocytopenia.
nd point definitions. The primary end point evaluated
as a rise in levels of troponin or CK-MB at 6 to 8 h or 16
o 24 h after PCI. Enzyme rise was defined as end point
hen troponin 0.2 mol/l or CK-MB 16 mmol/l.
s in the Two Treatment Arms Before
o Pre-Treatment
(n  102)
Pre-Treatment
(n  101)
60.3 (10.9) 62.1 (9.9)
22 (21.6) 24 (23.8)
11 (10.8) 18 (17.8)
35 (34.3) 49 (48.5)
59 (57.8) 73 (72.3)*
42 (41.2) 38 (37.6)
38 (37.3) 29 (28.7)
47 (46.1) 29 (27.8)*
15 (14.7) 15 (14.9)
6 (5.9) 13 (12.9)
92 (90.2) 84 (83.2)
55 (53.9) 49 (48.5)
62 (60.8) 53 (52.3)
1 (1.0) 4 (4.0)
74 (72.5) 80 (79.2)
97 (95.1) 96 (95.0)
15 (14.7) 25 (24.8)
4 (3.9) 1 (1.0)
1 (1.0) —
6 (6.0) —
5 (5.0) 6 (5.9)
28 (28.0) 31 (30.7)
53 (53.0) 57 (56.4)
8 (8.0) 7 (6.9)
II; CABG  coronary artery bypass grafting; CVD 
infarction; PTCA  percutaneous transluminal coronarytient
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Clopidogrel Pre-Treatment in Elective Stenting July 7, 2004:20–4Secondary end points were death, stroke, MI, CABG,
epeated PCI, and subacute stent thrombosis at one and six
onths. In addition, access site complications and acute
essel closure within 24 h after PCI were assessed. A
omposite end point was defined as death, stroke, MI,
ABG, repeated PCI, or subacute stent thrombosis at six
onths.
tatistical methods. All patients randomized to the two
tudy arms were included in the analysis. Baseline charac-
eristics between the pre-treated and the non–pre-treated
roup were compared by means of the chi-square test for
roportions and Student t test for continuous variables.
roportions of patients with elevated levels of troponin or
K-MB after 6 to 8 h and 16 to 24 h were compared
etween the two study groups using the chi-square test.
nalyses were repeated with additional adjustments for age,
ypercholesterolemia, previous MI, and the presence of
iabetes by way of logistic regression analysis. Secondary
nd points and the composite end point were compared
sing the chi-square test. An alpha value of 0.05 was
onsidered statistically significant. All analyses were per-
ormed with SPSS statistical software (SPSS Inc., Chicago,
llinois).
The reduction of risk of procedure-related myocardial
amage, defined as a rise in enzyme levels by pre-treatment
ith ticlopidine, was found in a previous study (9) to be
4%. Assuming a comparable effect of clopidogrel (10,11)
nd an incidence of a rise of enzymes in 29% (9) of patients,
ith a significance level of 0.05 and power of 0.9, a
inimum of 90 patients in each group would have been
ecessary to detect a statistically significant difference be-
ween groups. Accounting for losses of follow-up, we
ncluded 10 additional patients in each group.
ESULTS
f the 203 patients randomized, nine patients did not
ndergo coronary stent implantation, because of different
easons (no significant lesion, unable to cross the lesion with
he wire) or because they withdrew their informed consent.
e followed these patients according to the intention-to-
reat principle.
Baseline and angiographical characteristics in the two
roups are presented in Tables 1 and 2. The difference in
ypercholesterolemia was statistically significant (p 0.04).
history of MI and current smoking were slightly more
revalent in the non–pre-treated group, but only the differ-
nce in a history of MI was statistically significant (p 
.01). There was no difference between the study groups in
ngiographic characteristics or anginal class using the Ca-
adian Cardiovascular Society classification.
No significant difference was found in troponin I level rise
t 24 h above the clinically relevant level of 0.2 mol/l: a rise
n troponin was found in 42 (43.3%) non–pre-treated
atients versus 48 (51.1%) pre-treated patients (p  0.31).
he distribution of serum troponin I levels are shown in oigure 1. Analyses were repeated using a troponin I cut-off
evel of 0.5 mol/l, which did not change the results. Also,
o significant difference between non–pre-treated and pre-
reated patients could be observed in the percentage of
atients with a CK-MB elevation above 16 mmol/l (Table
). Analyses were repeated with adjustment for important
aseline variables, which did not change our findings. We
erformed a sub-group analysis on patients with a type C
esion, but also in this sub-group, no differences were
bserved between pre-treated and non–pre-treated patients.
Acute vessel closure within 24 h occurred once in the
on–pre-treated group. In 3 of the 203 patients, access site
omplications occurred: twice in the pre-treated and once in
he non–pre-treated group. None of these patients needed
lood transfusions or vascular surgery. No other hemor-
hagic complications were observed during the study period.
Follow-up at one and six months did not reveal a significant
able 2. Baseline Angiographical Characteristics of Patients in
he Two Treatment Arms Before and During Percutaneous
oronary Intervention
Characteristic
(Total, n  203)
No Pre-Treatment
(n  102)
Pre-Treatment
(n  101)
ne-vessel disease 35 (34) 44 (43)
wo-vessel disease 51 (50) 40 (39)
hree-vessel disease 11 (11) 13 (13)
ne lesion treated, n (%)
(n  121)
56 (55) 65 (64)
wo lesions treated, n (%)
(n  63)
36 (35) 27 (27)
hree lesions treated, n (%)
(n  9)
5 (5) 4 (4)
our lesions treated, n (%)
(n  1)
0 (0) 1 (1)
o PTCA performed, n (%)
(n  9)
5 (5) 4 (4)
P IIb/IIIa inhibitors
during PTCA, n (%)
19 (18.6) 14 (14)
rolonged chest pain during
PTCA, n (%)
5 (5) 4 (4)
bbreviations as in Table 1.
igure 1. Scatter plot showing the distribution of highest troponin values
f patients in the two treatment regimes.
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July 7, 2004:20–4 Clopidogrel Pre-Treatment in Elective Stentingifference between the two treatment groups concerning death,
troke, MI, CABG, repeated PCI, subacute stent thrombosis,
r a composite of these end points (Table 4).
ISCUSSION
he present study is one of the first randomized compari-
ons of pre-treatment with clopidogrel versus conventional
reatment initiated after elective coronary stent implanta-
ion. No difference between non–pre-treated and pre-
reated patients in the occurrence of elevation of troponin I
r CK-MB levels was observed. Adjustment for possible
onfounding factors did not alter these findings. We did not
etect any difference in clinical events.
Elevation of cardiac markers after PCI is associated with
orse long-term outcome (12–14). We chose the rise in
nzyme levels as the primary end point in the study because
he power of the study is markedly increased compared with
nalyzing clinical events. Compared with other studies
xamining minimal myocardial damage after elective PCI,
e found a slightly higher percentage of patients with a
ise in troponin I levels (14). On the other hand, the
requency of the rise in CK-MB levels was similar to other
ublications (12), although some CK-MB elevation
ight have remained undetected because of the sampling
indow.
Few studies have focused on the effect of pre-treatment
Table 3. Effect of Pre-Treatment on CK-MB
Outcome No P
CK-MB  16 after 6–8 h, n (%)
CK-MB  16 after 16–24 h, n (%)*
Troponin  0.2 after 6–8 h, n (%) 1
Troponin  0.2 after 16–24 h, n (%)* 4
*Highest value in 24 h.
CK-MB  creatine kinase-MB fraction.
Table 4. Effect of Pre-Treatment on Outcome
Composite End Point After Six Months
Total, n  203
No Pre-Tre
(n  10
One month
Subacute stent thrombosis —
Repeated PCI 3 (3%
MI 0
CABG 1 (1%
Death —
Stroke —
Six months
Repeated PCI 5 (5%
MI 3 (3%
CABG 1 (1%
Death 1 (1%
Stroke 1 (1%
Composite end point* 11 (12%
*The composite end point consisted of death, stroke, MI
intervention (PCI) after six months and was counted in a cuAbbreviations as in Table 1.ith clopidogrel in patients undergoing stent implantation.
n a retrospective study by Steinhubl et al. (9), pre-
reatment of patients with ticlopidine three days before
oronary stent implantation was associated with a large
eduction in post-procedural cardiac enzyme rise. The
CI-CURE study showed a large reduction of MI and
rgent revascularization in patients pre-treated with clopi-
ogrel. In contrast to our group, the study cohort consisted
f patients with unstable coronary syndromes. In another
ecent study of Berglund et al. (13), clopidogrel treatment
efore coronary stent implantation reduced the incidence of
composite of death, MI, and urgent revascularization by
1% compared with a historical control group of patients
reated in the preceding period. Like the aforementioned
tudy, this study was not randomized and also focused on
atients with unstable coronary syndromes. A sub-study of
he Do Tirofiban and ReoPro Give Similar Efficacy Out-
omes (TARGET) trial, mainly consisting of unstable
atients, did reveal a benefit in clinical outcome for pre-
reated patients. However, the choice for pre-treatment was
eft at the discretion of the interventional cardiologists
4–6,9,15,16).
The CREDO study, a randomized study of 2,116 pa-
ients with stable angina pectoris, did not detect a significant
ifference between patients pre-treated with clopidogrel or
lacebo between 3 and 24 h before PCI; an 18.5% risk
Troponin Elevation at 8 and 24 h
eatment Pre-Treatment
p Value for
Difference
%) 3 (3.2%) 1.00
%) 7 (7.4%) 0.78
2%) 19 (20.4%) 0.70
3%) 48 (51.1%) 0.31
nts at One and Six Months and the
t Pre-Treatment
(n  101)
p Value for
Difference
— —
1 (1%) 0.37
1 (1%) 1.0
2 (2%) 1.0
— —
— —
8 (8%) 0.57
0 0.12
2 (2%) 1.0
1 (1%) 1.0
0 0.50
13 (13%) 0.82
cute stent thrombosis, CABG, or repeated percutaneous
ive and mutually exclusive fashion.and
re-Tr
3 (3.3
6 (6.3
5 (17.
2 (43.Eve
atmen
2)
)
)
)
)
)
)
)
)
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Clopidogrel Pre-Treatment in Elective Stenting July 7, 2004:20–4eduction did not reach statistical significance (p  0.23).
owever, a better clinical outcome in patients pre-treated
or more than 6 h before PCI was observed. The results of
ur study do not confirm hypotheses generated from earlier
etrospective, non-randomized studies of beneficial pre-
reatment with clopidogrel. Mann et al. (8) also could not
etect a benefit in clinical outcome among stable patients
ithout insulin-requiring diabetes undergoing elective stent
mplantation. Recently, the Intracoronary Stenting and
ntithrombotic Regimen-Rapid Early Action for Coronary
reatment (ISAR-REACT) study was published, which
tudied the additional effect of a GP IIb/IIIa inhibitor in
ddition to pre-treatment with clopidogrel in patients with
table coronary syndromes. No beneficial effect was ob-
erved in patients treated with abciximab compared with
lacebo. According to the authors, pre-treatment with
lopidogrel prevented an additive anti-platelet effect of
bciximab, although all patients received pre-treatment with
lopidogrel (7,8,17).
The effect of pre-treatment with clopidogrel is thought to
e the result of earlier blockage of platelet aggregation and
hus better prevention of peri-procedural thrombus forma-
ion. We were unable to support this mechanism in elective
tent implantation among patients with stable angina pec-
oris. Blocking platelet aggregation in stable and thus less
hrombogenic patients may be the reason that we could not
etect any protective action of pre-treatment with clopi-
ogrel in patients undergoing elective stent implantation.
ome studies (7,8) do support this finding in detecting no
enefit of pre-treatment in stable patients, although recent
ata seem to contradict this (17). However, optimizing
nti-platelet therapy before PCI in patients with acute
oronary syndromes remains of great importance (4,15,16).
In our patient population we did not detect a decrease in
yocardial damage in patients pre-treated with clopidogrel
hree days before elective stent implantation. It is likely that
re-treatment with clopidogrel in this group of patients is
ot beneficial. However, the sample size of this study was
mall, and larger randomized clinical trials may be necessary
o verify our results.
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